Diaxonhit Agrees to Commercialize in Europe the CareDx AlloMa® Heart Transplant Test Following the Completion of Exclusive License Agreement

Published: Jun 27, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Diaxonhit (Paris:ALEHT), the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company focused on non-invasive tests for transplantation and autoimmune disease, today announced that they have entered into a definitive exclusive license and distribution agreement to market and perform AlloMap Molecular Expression Testing (AlloMap®) in Europe.

Help employers find you! Check out all the jobs and post your resume.

Back to news